PPIDT00464
Drug Information
| Name | Loncastuximab tesirine |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB16222 |
| Type | biotech |
| Indication | Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma who have undergone two or more prior lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. The above indication is approved under accelerated FDA approval following the results of clinical studies. Continued approval is dependant upon the results of confirmatory clinical trials.[L33529] In Europe, Loncastuximab tesirine is approved for treatment of both adult and pediatric patients aged 12 years old or older for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) after two or more lines of systemic therapy.[L45211] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
10 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
10 mg/2mL
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P15391 | CD19 | B-lymphocyte antigen CD19 | Homo sapiens | binder | Link |
| enzyme | P08684 | CYP3A4 | Cytochrome P450 3A4 | Homo sapiens | unknown | Link |
| enzyme | P20815 | CYP3A5 | Cytochrome P450 3A5 | Homo sapiens | substrate | Link |
| transporter | P08183 | ABCB1 | ATP-dependent translocase ABCB1 | Homo sapiens | substrate | Link |